AU2023251864A1 - Immune cell inhibition by immune checkpoint engagers - Google Patents

Immune cell inhibition by immune checkpoint engagers Download PDF

Info

Publication number
AU2023251864A1
AU2023251864A1 AU2023251864A AU2023251864A AU2023251864A1 AU 2023251864 A1 AU2023251864 A1 AU 2023251864A1 AU 2023251864 A AU2023251864 A AU 2023251864A AU 2023251864 A AU2023251864 A AU 2023251864A AU 2023251864 A1 AU2023251864 A1 AU 2023251864A1
Authority
AU
Australia
Prior art keywords
cell
cells
ice
engager
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023251864A
Other languages
English (en)
Inventor
Tobias Deuse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2023251864A1 publication Critical patent/AU2023251864A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
AU2023251864A 2022-04-13 2023-04-11 Immune cell inhibition by immune checkpoint engagers Pending AU2023251864A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263330539P 2022-04-13 2022-04-13
US63/330,539 2022-04-13
US202363448081P 2023-02-24 2023-02-24
US63/448,081 2023-02-24
PCT/US2023/018189 WO2023200796A1 (en) 2022-04-13 2023-04-11 Immune cell inhibition by immune checkpoint engagers

Publications (1)

Publication Number Publication Date
AU2023251864A1 true AU2023251864A1 (en) 2024-10-03

Family

ID=88330149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023251864A Pending AU2023251864A1 (en) 2022-04-13 2023-04-11 Immune cell inhibition by immune checkpoint engagers

Country Status (7)

Country Link
US (1) US20250268949A1 (https=)
EP (1) EP4507727A4 (https=)
JP (1) JP2025513879A (https=)
CN (1) CN119183385A (https=)
AU (1) AU2023251864A1 (https=)
CA (1) CA3247422A1 (https=)
WO (1) WO2023200796A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177982A2 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Lilrb1 engager cells
WO2025098508A1 (zh) * 2023-11-10 2025-05-15 贝达药业股份有限公司 标记性多肽、治疗剂及其应用
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
CN120340611B (zh) * 2025-04-02 2025-09-23 中瑞德泰生物科技集团有限公司 Car-nk细胞数据的特征提取方法及系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488876A1 (en) * 2002-06-13 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
JP2020506943A (ja) * 2017-02-07 2020-03-05 メモリアル スローン ケタリング キャンサー センター 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
US11840575B2 (en) * 2019-05-07 2023-12-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting BCMA and their uses thereof

Also Published As

Publication number Publication date
JP2025513879A (ja) 2025-04-30
EP4507727A1 (en) 2025-02-19
WO2023200796A1 (en) 2023-10-19
CA3247422A1 (en) 2023-10-19
EP4507727A4 (en) 2026-04-08
US20250268949A1 (en) 2025-08-28
CN119183385A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
US20240043803A1 (en) Innate immune cell silencing by sirp-alpha engager
US20250268949A1 (en) Immune cell inhibition by immune checkpoint engagers
CN111247242B (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
AU2018388413B2 (en) Enhanced immune effector cells and use thereof
US20220169988A1 (en) Gene-edited natural killer cells
AU2021228708A1 (en) Methods of making chimeric antigen receptor-expressing cells
AU2020274027A1 (en) Modified pluripotent cells
JP2015528298A (ja) 多重鎖キメラ抗原受容体およびその使用
US20240033355A1 (en) ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS
JP2024534772A (ja) 同種異系細胞療法用の遺伝子改変細胞
WO2024046394A1 (zh) 增强受体、表达增强受体的免疫细胞及其用途
JP2024526237A (ja) 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用
US20250032544A1 (en) Sirpalpha switch receptors
WO2024177978A1 (en) Lilrb3 engager cells
WO2024177975A2 (en) Tim3 engager cells
WO2024177982A2 (en) Lilrb1 engager cells
US20250388646A1 (en) Enhancing effector cell durability and efficacy in adoptive cell therapies
US20250230470A1 (en) Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2026072856A2 (en) Comprehensively immune protected cells
WO2025054202A1 (en) Method of screening a sample comprising a transgene with a unique barcode
WO2024097800A1 (en) Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2
WO2024097901A1 (en) Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b
WO2023164440A9 (en) Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses